NEW YORK (GenomeWeb News) – Asuragen today announced that it has spun out its microRNA-based therapeutics intellectual property into a new company called Mirna Therapeutics.
Specific details about the structure and focus of Mirna were not disclosed.
“The discovery of miRNAs represents a paradigm-changing event in biology and medicine of a magnitude that only occurs once every decade or two," Asuragen CEO and CSO Matt Winkler said in a statement. “They likely will become a major new class of drugs.”
As reported by GenomeWeb Daily News sister publication RNAi News in January, the new company is initially being funded with $3 million from Asuragen.